

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sincere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

CHANGE OF IMPORTANT EXECUTIVE FUNCTIONS OF DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Sincere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. TANG Renhong (“**Mr. Tang**”), an executive Director and the Co-chief Executive Officer of the Company (the “**Co-CEO**”), will resign from the position of the Co-CEO with effect from December 31, 2022 due to work rearrangement. Mr. Tang will remain as an executive Director of the Company and will be appointed by the Group as the chairman of the board of directors and chief executive officer of Sincere Zaiming Pharmaceutical Co., Ltd. (先聲再明醫藥有限公司), a subsidiary of the Company (“**Sincere Zaiming**”), with effect from January 1, 2023.

Mr. Tang will focus on the overall leading of the business affairs of Sincere Zaiming, which is responsible for the research and development, production and marketing of oncology pharmaceuticals of the Group.

Mr. Tang has confirmed that he has no disagreement with the Board and there is no matter in respect of his resignation as the Co-CEO that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

By order of the Board of
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, December 30, 2022

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. TANG Renhong and Mr. WAN Yushan as the executive Directors; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.